William Blair Maintains Neurogene(NGNE.US) With Buy Rating

威廉博萊維持Neurogene(NGNE.US)買入評級

moomoo資訊 · 2024/11/12 18:37 · 評級/大行評級

William Blair analyst Sami Corwin maintains $Neurogene (NGNE.US)$ with a buy rating.

According to TipRanks data, the analyst has a success rate of 50.8% and a total average return of 4.1% over the past year.

AnalystRecentRatingAutoNews_84649510670731_20241112_f45bc2632cdf1bf5ce0b8758ee53388f75a6e418_1731493988540633_mm_en

Furthermore, according to the comprehensive report, the opinions of $Neurogene (NGNE.US)$'s main analysts recently are as follows:

Preliminary NGN-401 Phase 1/2 data appear to surpass the efficacy benchmarks, demonstrating what seems to be a genuine clinical improvement in 4 pediatric Rett patients. The most significant concern may revolve around the 'emerging SAE' observed at the high dose of NGN-401 and the potential implications for the program's risk profile. Notably, the efficacy of NGN-401 to date is observed at the lower dose, which has seemingly exhibited a relative safety.
The company's Phase 1/2 readout has been recognized as a validation of NGN-401 in Rett syndrome, demonstrating unprecedented and potentially approvable efficacy, coupled with favorable safety at a lower dose. Nonetheless, investor attention has been drawn to uncertainty surrounding a treatment-related serious adverse event in the high dose cohort.
The sentiment towards Neurogene's shares is positive following the announcement of initial interim clinical data for its gene therapy NGN-401 in Rett syndrome. It is believed that the efficacy data is, more likely than not, sufficient to back its approval.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

威廉博萊分析師Sami Corwin維持$Neurogene (NGNE.US)$買入評級。

根據TipRanks數據顯示，該分析師近一年總勝率為50.8%，總平均回報率為4.1%。

AnalystRecentRatingAutoNews_84649510670731_20241112_f45bc2632cdf1bf5ce0b8758ee53388f75a6e418_1731493988540633_mm_tc

此外，綜合報道，$Neurogene (NGNE.US)$近期主要分析師觀點如下：

NGN-401 1/2 期初步數據似乎超過了療效基準，這表明 4 名兒科 Rett 患者的臨床狀況似乎得到了真正的改善。最重要的擔憂可能圍繞在高劑量 NGN-401 下觀察到的「新興SAE」及其對該計劃風險狀況的潛在影響。值得注意的是，迄今爲止，NGN-401 的療效是在較低的劑量下觀察到的，這似乎表現出相對的安全性。
該公司的1/2期讀數被公認爲對雷特綜合徵中 NGN-401 的驗證，顯示出前所未有且可能獲得批准的療效，同時在較低劑量下具有良好的安全性。儘管如此，圍繞高劑量隊列中與治療相關的嚴重不良事件的不確定性引起了投資者的注意。
在宣佈其治療雷特綜合徵的基因療法 NGN-401 的初步中期臨床數據後，人們對Neurogene股票的情緒樂觀。據信，療效數據很可能足以支持其批准。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

William Blair Maintains Neurogene(NGNE.US) With Buy Rating

William Blair Maintains Neurogene(NGNE.US) With Buy Rating

風險及免責聲明

聲明